GLP-1 Companion Meals Target Users of Weight-Loss Drugs
Food brands are launching protein-dense, smaller-portion meals labelled for users of appetite-reducing drugs such as semaglutide and tirzepatide, and Nestle's Vital Pursuit and Conagra's Healthy Choice have added companion ranges. Clinically Formulated Condition-Specific Meals grow about 11.8% a year, and gross margins run 34% to 46%. The trend needs nutrition science, dietitian input and careful claims, and it rewards brands with clinical partners and retailer ties, while drug users may buy fewer calories overall, and claim rules limit wording. Buyers judge suppliers on consistency, documentation and delivery reliability. Makers with scale and clear plans hold the strongest positions.
Market Impact: 1 billion people live with obesity








